Objective:
To determine whether polymorphisms of SLC22A1 and SLCO1B3 genes
could predict imatinib (IM) response and chronic myeloid leukemia (CML)
risk.
Methods:
We genotyped SLC22A1 (c.480G > C, c.1222A > G) and SLCO1B3
(c.334T > G, c.699G > A) polymorphisms in 132 patients with CML
and 109 sex- and age-matched healthy subjects. The patients were
evaluated for cytogenetic response by standard chromosome banding
analysis (CBA).
Results:
Polymorphism analysis showed significant increased risk of IM
resistance for SLC22A1c.1222AG (P = .03; OR = 2.2), SLCO1B3c.334TT/TG
genotypes (P = .007; OR = 4.37) and 334T allele (P = .03; OR = 2.86).
The double combinations of SLC22A1c.480CC and c.1222AG polymorphisms
with SLCO1B3c.334TT/TG were significantly associated with complete
cytogenetic response (CCyR) (P <.05; OR> 7). The interaction
between all polymorphisms and smoking were associated with CML
development and IM resistance (P ≤.04; OR> 3).
Conclusions:
Our study results suggest the influence of SLC22A1 and SLCO1B3
polymorphisms and the interaction of smoking on CML development and IM
response.